Kura Oncology Statistics
Share Statistics
Kura Oncology has 77.76M shares outstanding. The number of shares has increased by 3.18% in one year.
| Shares Outstanding | 77.76M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.6% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 65.25M |
| Failed to Deliver (FTD) Shares | 66 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 10.80M, so 13.89% of the outstanding shares have been sold short.
| Short Interest | 10.80M |
| Short % of Shares Out | 13.89% |
| Short % of Float | 16.6% |
| Short Ratio (days to cover) | 18.69 |
Valuation Ratios
The PE ratio is -6.9 and the forward PE ratio is -6.96.
| PE Ratio | -6.9 |
| Forward PE | -6.96 |
| PS Ratio | 0 |
| Forward PS | 87.6 |
| PB Ratio | 2.65 |
| P/FCF Ratio | -8.42 |
| PEG Ratio | n/a |
Enterprise Valuation
Kura Oncology Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 12.26, with a Debt / Equity ratio of 0.03.
| Current Ratio | 12.26 |
| Quick Ratio | 12.26 |
| Debt / Equity | 0.03 |
| Total Debt / Capitalization | 2.66 |
| Cash Flow / Debt | -11.52 |
| Interest Coverage | -107.04 |
Financial Efficiency
Return on equity (ROE) is -0.38% and return on capital (ROIC) is -40%.
| Return on Equity (ROE) | -0.38% |
| Return on Assets (ROA) | -0.34% |
| Return on Capital (ROIC) | -40% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.07M |
| Employee Count | 142 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -21.95% in the last 52 weeks. The beta is 0.86, so Kura Oncology 's price volatility has been higher than the market average.
| Beta | 0.86 |
| 52-Week Price Change | -21.95% |
| 50-Day Moving Average | 15.48 |
| 200-Day Moving Average | 19.3 |
| Relative Strength Index (RSI) | 21.2 |
| Average Volume (20 Days) | 1.33M |
Income Statement
In the last 12 months, Kura Oncology had revenue of $0 and earned -$152.63M in profits. Earnings per share was $-2.08.
| Revenue | 0 |
| Gross Profit | -849.00K |
| Operating Income | -165.80M |
| Net Income | -152.63M |
| EBITDA | -164.96M |
| EBIT | - |
| Earnings Per Share (EPS) | -2.08 |
Balance Sheet
The company has $37.32M in cash and $17.20M in debt, giving a net cash position of $20.12M.
| Cash & Cash Equivalents | 37.32M |
| Total Debt | 17.20M |
| Net Cash | 20.12M |
| Retained Earnings | -721.44M |
| Total Assets | 478.84M |
| Working Capital | 422.82M |
Cash Flow
In the last 12 months, operating cash flow was -$124.82M and capital expenditures -$168.00K, giving a free cash flow of -$124.99M.
| Operating Cash Flow | -124.82M |
| Capital Expenditures | -168.00K |
| Free Cash Flow | -124.99M |
| FCF Per Share | -1.71 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
KURA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -21.67% |
| FCF Yield | -16.74% |
Analyst Forecast
The average price target for KURA is $32, which is 233.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $32 |
| Price Target Difference | 233.3% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Scores
| Altman Z-Score | 5.82 |
| Piotroski F-Score | 3 |